SIBP-A18

Phase 1Small molecule

SShanghai Institute Of Biological Products

SIBP-A18 is one of 3 small molecule programs targeting Advanced Malignant Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumorRecruiting

Advanced Malignant Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Advanced Malignant Solid Tumor

#DrugCompanyPhaseTrials

BNT314

BioNTech

Phase 1

1 2

MHB039A

MMinghui Pharmaceutical (Hangzhou) Ltd

Preclinical

1 3

SIBP-A18

SShanghai Institute Of Biological Products

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Advanced Malignant Solid Tumor

NCT06985368

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumor1 trial

A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT06985368·156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SIBP-A18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIBP-A18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIBP-A18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Institute Of Biological Products company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Institute Of Biological Products

SIBP-A18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Advanced Malignant Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News